The early bactericidal activity of anti-tuberculosis drugs: a literature review
The early bactericidal activity of anti-tuberculosis drugs: a literature review
复制标题
DOI：
10.1016/s1472-9792(08)70038-6
复制
发表时间：
2008-08-01
期刊：
影响因子：
3.2
通讯作者：
Diacon, A. H.
中科院分区：
文献类型：
--
作者：
Donald, P. R.;Diacon, A. H.
从抗结核化疗的早期开始，肺结核患者痰中分枝杆菌的定量就被用来评估患者对治疗的反应。最近，抗结核药物的早期杀菌活性（EBA），即治疗早期痰液中结核分枝杆菌活菌落形成单位的下降，已被证明是一种客观、可重复的药物杀死痰涂片阳性肺结核患者痰液中代谢活性杆菌能力的指标。EBA提供了一个机会，可以快速证明一种新药在相对少数的患者中具有可检测的抗结核作用，最合适的剂量是什么，以进行更广泛的临床试验，并允许研究药代动力学和杀菌活性之间的关系以及相关药物的毒性。(c)2008爱思唯尔有限公司保留所有权利。
Quantification of mycobacteria in sputum from pulmonary tuberculosis patients has been used to evaluate patient's response to treatment since the earliest days of anti-tuberculosis chemotherapy. More recently the early bactericidal activity (EBA) of anti-tuberculosis agents, measured as the fall in viable colony forming units of Mycobacterium tuberculosis in sputum early in therapy, has been shown to be an objective, repeatable measure of the ability of an agent to kill the metabolically active bacilli found in the sputum of patients with sputum microscopy smear-positive pulmonary tuberculosis. EBA offers an opportunity to rapidly demonstrate that a new agent has a detectable anti-tuberculosis effect in a relatively small number of patients, what the most appropriate dose is to take forward to more extensive clinical trials and allows the study of the relationship between pharmacokinetics and bactericidal activity and toxicity of the relevant agent. (c) 2008 Elsevier Ltd. All rights reserved.